Fulcrum Therapeutics Inc. (FULC)
NASDAQ: FULC
· Real-Time Price · USD
9.58
0.34 (3.68%)
At close: Oct 08, 2025, 10:20 AM
3.68% (1D)
| Bid | 9.57 |
| Market Cap | 518.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.22M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -8.12 |
| Forward PE | -7.98 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.6 |
| Volume | 33,184 |
| Avg. Volume (20D) | 650,757 |
| Open | 9.40 |
| Previous Close | 9.24 |
| Day's Range | 9.39 - 9.63 |
| 52-Week Range | 2.31 - 9.70 |
| Beta | 2.93 |
| Ex-Dividend Date | n/a |
About FULC
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FULC
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FULC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-2.82%
Fulcrum Therapeutics shares are trading lower foll...
Unlock content with
Pro Subscription
2 months ago
+0%
Fulcrum Therapeutics shares are trading higher after the company announced it will present topline results from the 12 mg dose cohort of its Phase 1b PIONEER trial.
